SLN (Silence Therapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


SLN Silence Therapeutics PLC SLN
44 GF Score
Price $10.44
GF Value $0.35
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Long-Term Debt?

Silence Therapeutics SLN -0.95% 44 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates SLN with a GF Score™ of 44/100 and a GF Value™ of $0.35 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Silence Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Silence Therapeutics  (NAS:SLN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Silence Therapeutics Long-Term Debt Related Terms

Silence Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Long-Term Debt Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Silence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SLN
44GF Score
Silence Therapeutics PLC SLN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Silence Therapeutics (SLN) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Silence Therapeutics' Long-Term Debt too high?
Silence Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Long-Term Debt compare to IMRX and VRXA?
Silence Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Silence Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.35, compared to a current price of $10.44 — trading 2882.9% above its estimated fair value. The current Long-Term Debt is $0.00 Mil. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $10.44 is trading 2882.9% above its estimated GF Value™ of $0.35. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $0.35 vs. price of $10.44 (2882.9% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score

Get the complete analysis for SLN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.44
Price
$0.35
GF Value